Pfizer Canada’s IXIFI (infliximab for injection) will be available in Canada as of April 1, 2025. IXIFI is a biosimilar to Remicade (infliximab). It was approved by ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes ...

To read all of these articles and more, visit centerforbiosimilars.com.

As Remdantry uses the same Drug Identification Number (DIN) as Inflectra ®, the formulation, indications and dosages of Remdantry will remain the same as that of Inflectra, which was originally ...

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian ...

Celltrion developed and manufactured the world’s first monoclonal antibody biosimilar, followed by the first and only subcutaneous (SC) formulation infliximab, ‘Remsima ® SC’, which was also approved ...